The FDA has granted approval for the use of Spravato nasal spray, developed by Johnson & Johnson (JNJ.US), for the treatment of adult patients suffering from treatment-resistant depression (TRD).

Johnson & Johnson (JNJ.US) announced on January 21 that the FDA has approved its Spravato (esketamine) nasal spray for the treatment of adults with treatment-resistant depression (TRD). The trial showed that Spravato reached the primary endpoint at week 4. It also showed a rapid and significant improvement in depressive symptoms compared to placebo as early as 24 hours. According to the press release, Spravato is the first single-agent therapy approved for the treatment of adult depression (MDD) patients who have not adequately responded to at least two oral antidepressants.